Brooke L. Billman

Brooke L. Billman

Auto-generated profile, based on publicly available information

Brooke L. Billman

Jason D. Merker and Maximilian Diehn, Stanford University School of Medicine; Stanford, CA; Geoffrey R. Oxnard, Dana Farber Cancer Institute and Harvard Medical School; Neal Lindeman, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Carolyn Compton, Arizona State University, Tempe, AZ; Patricia Hurley, Richard L. Schilsky, Thomas K. Oliver, and Suanna S. Bruinooge, American So

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJason D. Merker
Jason D. Merker
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
CCCarolyn Compton
Carolyn Compton
MDMaximilian Diehn
Maximilian Diehn
PHPatricia Hurley
Patricia Hurley
NTNicholas C. Turner
Nicholas C. Turner
Purpose: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from ASCO and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods: An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including pre-analytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results: The literature search identified 1,338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusion: The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity and clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, re-evaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.

5 March 2018 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
JMJason D. Merker
Jason D. Merker
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
CCCarolyn Compton
Carolyn Compton
MDMaximilian Diehn
Maximilian Diehn
PHPatricia Hurley
Patricia Hurley
NTNicholas C. Turner
Nicholas C. Turner
Purpose.—: Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology and the College of American Pathologists summarizes current information about clinical ctDNA assays and provides a framework for future research. Methods.—: An Expert Panel conducted a literature review on the use of ctDNA assays for solid tumors, including preanalytical variables, analytical validity, interpretation and reporting, and clinical validity and utility. Results.—: The literature search identified 1338 references. Of those, 390, plus 31 references supplied by the Expert Panel, were selected for full-text review. There were 77 articles selected for inclusion. Conclusions.—: The evidence indicates that testing for ctDNA is optimally performed on plasma collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours of collection. Some ctDNA assays have demonstrated clinical validity and utility with certain types of advanced cancer; however, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows discordance between the results of ctDNA assays and genotyping tumor specimens, and supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in early-stage cancer, treatment monitoring, or residual disease detection. There is no evidence of clinical validity or clinical utility to suggest that ctDNA assays are useful for cancer screening, outside of a clinical trial. Given the rapid pace of research, reevaluation of the literature will shortly be required, along with the development of tools and guidance for clinical practice.

1 August 2020 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
Sinchita Roy-ChowdhuriSinchita Roy-Chowdhuri
Sinchita Roy-Chowdhuri
SDSanja Dacic
Sanja Dacic
MGMohiedean Ghofrani
Mohiedean Ghofrani
PIPeter B. Illei
Peter B. Illei
LLLester J. Layfield
Lester J. Layfield
CGChristopher R. Gilbert
Christopher R. Gilbert
Context.—: The need for appropriate specimen use for ancillary testing has become more commonplace in the practice of pathology. This, coupled with improvements in technology, often provides less invasive methods of testing, but presents new challenges to appropriate specimen collection and handling of these small specimens, including thoracic small biopsy and cytology samples. Objective.—: To develop a clinical practice guideline including recommendations on how to obtain, handle, and process thoracic small biopsy and cytology tissue specimens for diagnostic testing and ancillary studies. Methods.—: The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. Core needle biopsy, touch preparation, fine-needle aspiration, and effusion specimens with thoracic diseases including malignancy, granulomatous process/sarcoidosis, and infection (eg, tuberculosis) were deemed within scope. Ancillary studies included immunohistochemistry and immunocytochemistry, fluorescence in situ hybridization, mutational analysis, flow cytometry, cytogenetics, and microbiologic studies routinely performed in the clinical pathology laboratory. The use of rapid on-site evaluation was also covered. Results.—: Sixteen guideline statements were developed to assist clinicians and pathologists in collecting and processing thoracic small biopsy and cytology tissue samples. Conclusions.—: Based on the systematic review and expert panel consensus, thoracic small specimens can be handled and processed to perform downstream testing (eg, molecular markers, immunohistochemical biomarkers), core needle and fine-needle techniques can provide appropriate cytologic and histologic specimens for ancillary studies, and rapid on-site cytologic evaluation remains helpful in appropriate triage, handling, and processing of specimens.

1 April 2016 in Journal of the Medical Library Association
Verified
Journal Article
Open access
SLSusan Lessick
Susan Lessick
CPCarol Perryman
Carol Perryman
BBBrooke L Billman
Brooke L Billman
KAKristine M Alpi
Kristine M Alpi
SGSandra L De Groote
Sandra L De Groote
TBTed D Babin
Ted D Babin
The extent to which health sciences librarians are engaged in research is a little-studied question. This study assesses the research activities and attitudes of Medical Library Association (MLA) members, including the influence of work affiliation.An ...

25 February 2021 in Hypothesis
Verified
Journal Article
Open access
ASAngela Spencer
Angela Spencer
EMElizabeth Mamo
Elizabeth Mamo
BBBrooke L. Billman
Brooke L. Billman
Objectives: To assess the current landscape of hospital libraries by collecting benchmarking data from hospital librarians in the U.S. and other countries. Since the last MLA benchmarking survey in 2002 hospital libraries have faced significant changes including downsizing, position and library elimination, and hospital mergers. This survey will provides information to inform the development and implementation of effective advocacy for hospital libraries. Methods: A web-based, anonymous survey was designed to collect information from hospital librarians representing stand-alone hospitals and hospital systems. The 57-question survey was distributed via select list servs, targeting the US and Canada but open to any country. The topic areas covered hospital/health system, library, and library staff demographics; library characteristics and scope of service; interlibrary loan and document delivery; library funding; and library budget. Hospital library benchmarking surveys, including the previous MLA surveys, were reviewed and applicable questions were added. Results: There were a total of 180 respondents but the total number of responses for each question varied. Select results are as follows: of the responding libraries, 67.2% were part of a hospital system; 24.4% had merged with or were bought by another hospital or health system and, of those, 77.1% had acquired 1-5 hospitals in the last 10 years; 77.9% were not for profits; over half (55.2%) had <5,001 FTE in the organization; 56.9% had one library; 47.7% had 1 FTE librarian, 34.9% had 2-5; 82.1% did not or were not able to use social media; 60.7% didn’t have strategic plans; 66.1% belonged to a consortium; 48.2% provided up to 250 search requests a year; 66.3% did not receive funding outside of their organization; 32.5% had budgets for print books totaling less than $1,000; 30.1% had budgets, excluding salaries, of less than $100,000 and 9.7% had budgets over $1M. Conclusions: These findings contribute to the field’s knowledge of hospital library demographics as well as the services provided. The results suggest implications for hospital librarians regarding staffing levels and the depth of services within their unique settings, especially within the context of rapidly expanding health systems.

23 October 2012 in Medical Reference Services Quarterly
Verified
Journal Article
Closed access
KCKeith W. Cogdill
Keith W. Cogdill
LALorely Ambriz
Lorely Ambriz
BBBrooke L. Billman
Brooke L. Billman
KCKathleen V. Carter
Kathleen V. Carter
BNBarbara Nail-Chiwetalu
Barbara Nail-Chiwetalu
ANAnnabelle V. Nuñez
Annabelle V. Nuñez
This article reviews the formation of the Frontera Collaboration, a coalition of health sciences librarians serving clinicians and public health personnel in the U.S.-Mexico border region. Based on findings from an assessment of the target populations’ learning needs, the Frontera Collaboration participants developed a shared set of training materials that have been used in pilot training sessions. The Frontera Collaboration's participants learned several lessons related to collaborative health information outreach and increased their understanding of the concerns and needs of clinicians and public health personnel serving border communities.